Dr sc. Branka Divović-Matović

Branka Divović Matović je rođena 05.01.1989. godine u Novoj Varoši. U istom mestu je završila Osnovnu školu i Gimnaziju „Pivo Karamatijević“ kao đak generacije i nosilac diplome ''Vuk Karadžić''. Na Farmaceutskom fakultetu Univerziteta u Beogradu diplomirala je 2013. godine sa prosečnom ocenom 9,78. 2020. godine završila je akademsku specijalizaciju Farmakoterapija u farmaceutskoj praksi i stekla zvanje specijalista farmacije.  Doktorske akademske studije iz farmakologije upisala je školske 2013/14. na Farmaceutskom fakultetu u Beogradu i u završnoj je fazi izrade doktorske disertacije (mentor prof. dr Miroslav Savić).

Od aprila 2014. godine radi kao istraživač-pripravnik na projektu koji finansira Ministarstvo prosvete, nauke i tehnološkog razvoja Republike Srbije, a od januara 2022. godine član je projektnog tima programa IDEJE Fonda za nauku Republike Srbije. Osnovna oblast istraživanja je bihejvioralna farmakologija.

U prolećnom semestru školske 2013/2014. bila je angažovana u realizaciji praktične nastave iz predmeta Toksikologija s analitikom u okviru integrisanih akademskih studija (Katedra za toksikologiju „Akademik Danilo Soldatović“, Farmaceutski fakultet Univerziteta u Beogradu).

Od oktobra 2014. godine zaposlena je na Katedri za farmakologiju, Farmaceutskog fakulteta Univerziteta u Beogradu, najpre kao saradnik u nastavi, potom kao asistent. Učestvuje u izvođenju praktične nastave iz obaveznih i izbornih predmeta koji se izvode na Katedri na integrisanim i specijalističkim akademskim studijama.

Od 2013 do 2019. godine pohađala je edukativne radionice, seminare, kongrese, škole:seminari „Uvod u preduzetništvo“ i „Menadžment“ u sklopu projekta Promocija nauke kroz preduzetništvo (2013); Federation of European Neuroscience Societes Featured Regional Meeting (Solun, 2015); moduli za obuku naučno-nastavnog osoblja u okviru programa „TRAIN“ (Training & Research for Academic Newcomers-TRAIN) (2017); letnja škola  Clinical Skills in the Treatment of Anxiety and Depression: Hands-on Practice and Heads-on Theory, na Radboud univezitetu, u Nijemgenu, Holandija (2019); 32nd European College of Neuropsychopharmacology (ECNP) Kongres (Kopenhagen, 2019). Dobitnica je granta ECNP CDE (country with a developing economy) za 2019. godinu.

• Knutson DE, Kodali R, Divović B, Treven M, Stephen MR, Zahn NM, Dobričić V, Huber AT, Meirelles MA, Verma RS, Wimmer L, Witzigmann C, Arnold LA, Chiou LC, Ernst M, Mihovilovic MD, Savić MM, Sieghart W, Cook JM. Design and synthesis of novel deuterated ligands functionally selective for the γ-aminobutyric acid type A receptor (GABA(A)R) α6 subtype with improved metabolic stability and enhanced bioavailability. J Med Chem. 2018 Mar 22;61(6):2422-2446. IF (2018): 6,054

• Mitrović JR, Divović-Matović B, Knutson DE, Đoković JB, Kremenović A, Dobričić VD, Randjelović DV, Pantelić I, Cook JM, Savić MM, Savić SD. Overcoming the Low Oral Bioavailability of Deuterated Pyrazoloquinolinone Ligand DK-I-60-3 by Nanonization: A Knowledge-Based Approach. Pharmaceutics. 2021 Jul 31;13(8):1188. doi: 10.3390/pharmaceutics13081188. IF (2020): 6,321
• Mitrović JR, Divović B, Knutson DE, et al. Nanocrystal dispersion of DK-I-56-1, a poorly soluble pyrazoloquinolinone positive modulator of α6 GABAA receptors: Formulation approach toward improved in vivo performance [published online ahead of print, 2020 Jun 18]. Eur J Pharm Sci. 2020;152:105432. IF (2019): 3,616
• Đorđević SM, Santrač A, Cekić ND, Marković BD, Divović B, Ilić TM, Savić MM, Savić SD. Parenteral nanoemulsions of risperidone for enhanced brain delivery in acute psychosis: Physicochemical and in vivo performances. Int J Pharm. 2017 May 25. pii: S0378-5173(17)30463-5. IF (2017): 3,862
• Vasović D, Divović B, Treven M, Knutson DE, Steudle F, Scholze P, Obradović A, Fabjan J, Brković B, Sieghart W, Ernst M, Cook JM, Savić MM. Trigeminal neuropathic pain development and maintenance in rats are suppressed by a positive modulator of α6GABA(A) receptors. Eur J Pain. 2019 Jan 11. IF (2019): 3,492
• Stamenić TT, Poe MM, Rehman S, Santrač A, Divović B, Scholze P, Ernst M, Cook JM, Savić MM. Ester to amide substitution improves selectivity, efficacy and kinetic behavior of a benzodiazepine positive modulator of GABA(A) receptors containing the α5 subunit. Eur J Pharmacol. 2016 Nov 15;791:433-443. IF (2016): 2.896
• Batinić B, Santrač A, Divović B, Timić T, Stanković T, Obradović AL, Joksimović S, Savić MM. Lipopolysaccharide exposure during late embryogenesis results in diminished locomotor activity and amphetamine response in females and spatial cognition impairment in males in adult, but not adolescent rat offspring. Behav Brain Res. 2015 Nov 24;299:72-80. IF (2015): 3,002
• Golani LK, Divović B, Sharmin D, Pandey KP, Mian MY, Cerne R, Zahn NM, Meyer MJ, Tiruveedhula VVNPB, Smith JL, Ping X, Jin X, Lippa A, Schkeryantz JM, Arnold LA, Cook JM, Savić MM, Witkin JM. Metabolism, pharmacokinetics, and anticonvulsant activity of a deuterated analog of the α2/3-selective GABAkine KRM-II-81. Biopharm Drug Dispos. 2022 Feb 22. doi: 10.1002/bdd.2313. IF (2020): 1,729
• Divović Matović B, Mitrović J, Knutson DE, Batinić B, Savić SD, Savić MM. Nanosuspension formulation of DK-I-56-1, a deuterated ligand functionally selective for the α6 GABAA receptors, induces hyperlocomotion in mice. 32nd European College of Neuropsychopharmacology (ECNP)  Congress, Copenhagen, Denmark, 7-10 September 2019
• Divović B, Batinić B, Timić Stamenić T, Santrač A, Savić M. Locomotor changes during habituation and saline- and amphetamine challenge in adult rats in utero exposed to LPS appear in adolescence in females only. FENS Featured Regional Meeting, Thessaloniki, Greece, 7 – 10 October, 2015.